systolic heart failure? Does load-induced ventricular hypertrophy progress to

[1]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[2]  M. Nieminen,et al.  Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. , 2004, JAMA.

[3]  J. Gardin,et al.  Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. , 2004, Journal of the American College of Cardiology.

[4]  S. Kudoh,et al.  Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II , 2004, Nature Cell Biology.

[5]  M. Province,et al.  Differences in Left Ventricular Structure Between Black and White Hypertensive Adults: The Hypertension Genetic Epidemiology Network Study , 2004, Hypertension.

[6]  W. Gaasch,et al.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. , 2004, The New England journal of medicine.

[7]  E. Olson,et al.  Hypertrophy of the heart: a new therapeutic target? , 2004, Circulation.

[8]  Mark A Sussman,et al.  Myocardial aging and senescence: where have the stem cells gone? , 2004, Annual review of physiology.

[9]  C. Leclercq,et al.  Ventricular resynchronization: current state of the art. , 2004, Circulation.

[10]  G. Dorn,et al.  Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men , 2004, Circulation.

[11]  M. Drazner,et al.  Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. , 2004, The American journal of cardiology.

[12]  Jian Xu,et al.  Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy , 2004, Circulation research.

[13]  R. Schwinger,et al.  Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure , 2004, European journal of heart failure.

[14]  O. Frazier,et al.  Mechanical Circulatory Support for Advanced Heart Failure: Where Does It Stand in 2003? , 2003, Circulation.

[15]  F. Al-Mohanna,et al.  A pressure overload model to track the molecular biology of heart failure. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[17]  G. Dorn,et al.  Phenotyping hypertrophy: eschew obfuscation. , 2003, Circulation research.

[18]  G. Dorn,et al.  Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. , 2003, The Journal of clinical investigation.

[19]  Salim Yusuf,et al.  Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study , 2003, Circulation.

[20]  Ulrike Mende,et al.  Dilated Cardiomyopathy and Heart Failure Caused by a Mutation in Phospholamban , 2003, Science.

[21]  J. Schaper,et al.  Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanisms , 2003, Circulation.

[22]  B. Carabello.  Concentric versus eccentric remodeling. , 2002, Journal of cardiac failure.

[23]  M. Packer.  The impossible task of developing a new treatment for heart failure. , 2002, Journal of cardiac failure.

[24]  M. Nieminen,et al.  Change in Systolic Left Ventricular Performance After 3 Years of Antihypertensive Treatment: The Losartan Intervention for Endpoint (LIFE) Study , 2002, Circulation.

[25]  H. Suga,et al.  Heart size-independent analysis of myocardial function in murine pressure overload hypertrophy. , 2002, American journal of physiology. Heart and circulatory physiology.

[26]  O. Ritter,et al.  Calcineurin in Human Heart Hypertrophy , 2002, Circulation.

[27]  K. Chien,et al.  Mixed signals in heart failure: cancer rules. , 2002, The Journal of clinical investigation.

[28]  Harvard Medical School,et al.  Targeting Phospholamban by Gene Transfer in Human Heart Failure , 2002, Circulation.

[29]  K. Chien,et al.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes , 2001, Nature Medicine.

[30]  D. Rao,et al.  Left Ventricular Systolic Dysfunction in a Biracial Sample of Hypertensive Adults: The HyperGEN Study , 2001, Hypertension.

[31]  W Grossman,et al.  LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. , 2001, American journal of physiology. Heart and circulatory physiology.

[32]  W. Haley,et al.  Effect of regression of left ventricular hypertrophy from systemic hypertension on systolic function assessed by midwall shortening (HOT echocardiographic study). , 2001, The American journal of cardiology.

[33]  S. Houser,et al.  Patients With End-Stage Congestive Heart Failure Treated With &bgr;-Adrenergic Receptor Antagonists Have Improved Ventricular Myocyte Calcium Regulatory Protein Abundance , 2001, Circulation.

[34]  E. Olson,et al.  Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy , 2001, The EMBO journal.

[35]  B. Howard,et al.  A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study. , 2001, American heart journal.

[36]  R. Hajjar,et al.  Differential Activation of Signal Transduction Pathways in Human Hearts With Hypertrophy Versus Advanced Heart Failure , 2001, Circulation.

[37]  G. Mancia,et al.  Midwall Mechanics Are Improved After Regression of Hypertensive Left Ventricular Hypertrophy and Normalization of Chamber Geometry , 2001, Circulation.

[38]  S. Houser,et al.  Abnormalities of calcium cycling in the hypertrophied and failing heart. , 2000, Journal of molecular and cellular cardiology.

[39]  B. Lorell,et al.  Left ventricular hypertrophy: pathogenesis, detection, and prognosis. , 2000, Circulation.

[40]  K. Chien.  Meeting Koch's postulates for calcium signaling in cardiac hypertrophy. , 2000, The Journal of clinical investigation.

[41]  J. Schwartz,et al.  Ambulatory Blood Pressure and M;etabolic Abnormalities in Hypertensive Subjects With Inappropriately High Left Ventricular Mass , 1999 .

[42]  M. Martone,et al.  Chronic Phospholamban–Sarcoplasmic Reticulum Calcium ATPase Interaction Is the Critical Calcium Cycling Defect in Dilated Cardiomyopathy , 1999, Cell.

[43]  S. Vanni,et al.  Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. , 1999, Circulation research.

[44]  G. Tomaselli,et al.  Electrophysiological remodeling in hypertrophy and heart failure. , 1999, Cardiovascular research.

[45]  J. Molkentin,et al.  Calcineurin and human heart failure , 1999, Nature Medicine.

[46]  M. Bristow.  Why does the myocardium fail? Insights from basic science , 1998, The Lancet.

[47]  R. Lefkowitz,et al.  Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. , 1998, Science.

[48]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[49]  K. Weber,et al.  Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. , 1997, Circulation.

[50]  L. Leinwand,et al.  Myosin heavy chain gene expression in human heart failure. , 1997, The Journal of clinical investigation.

[51]  D. Reda,et al.  Systolic function in hypertensive men with concentric remodeling. , 1997, Hypertension.

[52]  G. Dorn,et al.  Transgenic Gαq overexpression induces cardiac contractile failure in mice , 1997 .

[53]  D. Levy,et al.  Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. , 1997, The New England journal of medicine.

[54]  M. Swindle,et al.  Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. , 1997, Circulation.

[55]  G. Reboldi,et al.  Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. , 1996, The American journal of cardiology.

[56]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[57]  G. Aurigemma,et al.  Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. , 1995, Circulation.

[58]  D. Levy,et al.  Prognosis of left ventricular geometric patterns in the Framingham Heart Study. , 1995, Journal of the American College of Cardiology.

[59]  G. Reboldi,et al.  Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. , 1995, Journal of the American College of Cardiology.

[60]  J. Gottdiener,et al.  Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. , 1995, American journal of hypertension.

[61]  T. Doetschman,et al.  Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. , 1994, Circulation research.

[62]  J. Laragh,et al.  Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. , 1994, Journal of the American College of Cardiology.

[63]  M. Marcus,et al.  The heart in hypertension. , 1992, The New England journal of medicine.

[64]  J. Laragh,et al.  Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. , 1992, Journal of the American College of Cardiology.

[65]  W. Gaasch,et al.  Left Ventricular Midwall Mechanics in Systemic Arterial Hypertension Myocardial Function is Depressed in Pressure‐Overload Hypertrophy , 1991, Circulation.

[66]  C. Higgins,et al.  Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance studies in the morphologically abnormal left ventricle. , 1990, American heart journal.

[67]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[68]  W. Gaasch,et al.  Stress-shortening relations and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy. , 1989, Circulation.

[69]  O. Hess,et al.  Left ventricular systolic function in aortic stenosis. , 1988, European heart journal.

[70]  R. Bonow,et al.  Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. , 1987, The American journal of cardiology.

[71]  D. Levy,et al.  Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. , 1987, The American journal of cardiology.

[72]  W. Gaasch,et al.  Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements. , 1985, Circulation.

[73]  H. Krayenbuehl,et al.  Determinants of Ejection Performance in Aortic Stenosis , 1981, Circulation.

[74]  W. Grossman,et al.  Determinants of Ventricular Function in Pressure-Overload Hypertrophy in Man , 1979, Circulation.

[75]  N Reichek,et al.  Echocardiographic Determination of Left Ventricular Mass in Man: Anatomic Validation of the Method , 1977, Circulation.

[76]  W Grossman,et al.  Wall stress and patterns of hypertrophy in the human left ventricle. , 1975, The Journal of clinical investigation.

[77]  William Osler,et al.  The Principles and Practice of Medicine , 1892, Bristol Medico-Chirurgical Journal (1883).

[78]  G. Aurigemma,et al.  Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. , 2001, The American journal of cardiology.

[79]  A. Musarò,et al.  Research news , 2000, Nature Medicine.

[80]  J. Sadoshima,et al.  The cellular and molecular response of cardiac myocytes to mechanical stress. , 1997, Annual review of physiology.

[81]  D. Levy,et al.  Left Ventricular Hypertrophy and Risk of Cardiac Failure: Insights from the Framingham Study , 1987, Journal of cardiovascular pharmacology.

[82]  Meerson Fz.  On the mechanism of compensatory hyperfunction and insufficiency of the heart. , 1961 .